IMMUPHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.16 GBX | -0.92% |
|
-4.42% | +29.57% |
| Sales 2021 | 118K 147K | Sales 2022 | - | Capitalization | 6.13M 7.63M |
|---|---|---|---|---|---|
| Net income 2021 | -8M -9.95M | Net income 2022 | -3M -3.73M | EV / Sales 2021 | 126 x |
| Net cash position 2021 | 1.65M 2.05M | Net cash position 2022 | 668K 831K | EV / Sales 2022 | - |
| P/E ratio 2021 |
-2.03
x | P/E ratio 2022 |
-1.46
x | Employees | 13 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.46% | ||
| 1 week | -4.58% | ||
| Current month | +3.06% | ||
| 1 month | -2.23% | ||
| 3 months | +38.17% | ||
| 6 months | +27.55% | ||
| Current year | +31.37% |
1 week
2.10
2.49
1 month
1.983.00
Current year
0.823.00
1 year
0.823.80
3 years
0.8210.90
5 years
0.8232.20
10 years
0.82193.74
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 15-09-29 | |
Timothy Franklin
COO | Chief Operating Officer | 60 | 20-10-31 |
Lisa Baderoon
BRD | Director/Board Member | 57 | 12-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 15-09-29 | |
Timothy Franklin
COO | Chief Operating Officer | 60 | 20-10-31 |
Lisa Baderoon
BRD | Director/Board Member | 57 | 12-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 2.16 | -0.92% | 732 551 |
| 24-04-23 | 2.18 | -8.60% | 759,115 |
| 24-04-22 | 2.385 | +1.49% | 1,980,312 |
| 24-04-19 | 2.35 | +4.91% | 1,317,704 |
| 24-04-18 | 2.24 | -2.40% | 734,558 |
Delayed Quote London S.E., April 24, 2024 at 08:08 am EDT
More quotes
ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.
Calendar
2024-05-22
- Q4 2023 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +31.37% | 11.29M | |
| +3.13% | 43.43B | |
| +48.71% | 41.69B | |
| +8.49% | 41.31B | |
| -10.82% | 27.14B | |
| +8.26% | 25.28B | |
| -23.69% | 18.47B | |
| +32.83% | 12.59B | |
| +1.58% | 12.33B | |
| +6.63% | 11.03B |
- Stock Market
- Equities
- IMM Stock
